EFAVIRENZ by Aurobindo Pharma is efavirenz, emtricitabine and tenofovir disoproxil fumarate is a fixed-dose combination of antiviral drugs efv, ftc, and tdf [see ]. First approved in 2018.
Drug data last refreshed 20h ago
Efavirenz, emtricitabine and tenofovir disoproxil fumarate is a fixed-dose combination of antiviral drugs EFV, FTC, and TDF [see ].
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants
A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)
A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz
A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants
Worked on EFAVIRENZ at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.